Shares of Biohaven Ltd. (NYSE:BHVN – Get Rating) have received an average recommendation of "Moderate Buy" from the twelve analysts that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $58.32.

A number of analysts have recently weighed in on the company. BTIG Research assumed coverage on Biohaven in a research report on Friday, December 2nd. They set a "buy" rating and a $24.00 price target on the stock. Piper Sandler reduced their target price on Biohaven from $23.00 to $21.00 and set an "overweight" rating for the company in a report on Wednesday, October 26th. JPMorgan Chase & Co. assumed coverage on Biohaven in a report on Wednesday, January 4th. They set an "overweight" rating and a $23.00 price objective for the company. Cowen lowered their target price on shares of Biohaven to $25.00 in a research report on Monday, November 7th. Finally, SVB Securities assumed coverage on Biohaven in a research report on Tuesday, January 24th. They issued an "outperform" rating and a $24.00 price target on the stock.

Biohaven Price Performance

Biohaven stock opened at $16.98 on Monday. The stock's 50 day moving average price is $16.26 and its 200 day moving average price is $61.73. The company has a market cap of $1.16 billion, a PE ratio of -1.22 and a beta of 1.08. Biohaven has a 1-year low of $5.54 and a 1-year high of $20.57.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. US Bancorp DE grew its stake in Biohaven by 19.1% during the first quarter. US Bancorp DE now owns 586 shares of the company's stock valued at $70,000 after acquiring an additional 94 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in Biohaven by 311.8% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 280 shares of the company's stock valued at $41,000 after buying an additional 212 shares during the last quarter. Cetera Advisor Networks LLC raised its holdings in Biohaven by 8.1% during the 2nd quarter. Cetera Advisor Networks LLC now owns 3,030 shares of the company's stock valued at $442,000 after buying an additional 226 shares during the last quarter. Chartwell Investment Partners LLC raised its holdings in Biohaven by 2.6% in the 2nd quarter. Chartwell Investment Partners LLC now owns 10,741 shares of the company's stock worth $1,565,000 after purchasing an additional 268 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC raised its holdings in Biohaven by 13.3% in the 2nd quarter. O Shaughnessy Asset Management LLC now owns 2,286 shares of the company's stock worth $333,000 after purchasing an additional 268 shares in the last quarter. 98.01% of the stock is owned by institutional investors.

Biohaven Company Profile

(Get Rating)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.

Further Reading

• Get a free copy of the StockNews.com research report on Biohaven (BHVN)
• Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
• The Bottom Is In For Cloudflare Stock
• 3 Tickers Leading a Meme Stock Revival
• Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
• Wall Street Says These 3 Stocks Will Grow Earnings In 2023

Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.